Glenmark Pharmaceuticals is currently trading at Rs. 345.00, up by 5.30 points or 1.56% from its previous closing of Rs. 339.70 on the BSE.
The scrip opened at Rs. 336.40 and has touched a high and low of Rs. 350.00 and Rs. 336.40 respectively. So far 84561 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 706.90 on 31-Dec-2018 and a 52 week low of Rs. 267.30 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 350.00 and Rs. 322.70 respectively. The current market cap of the company is Rs. 9788.41 crore.
The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.80% and 14.62% respectively.
Glenmark Pharmaceuticals has received certificate of compliance for Baddi manufacturing facility from European regulator, SUKL (State Institute for Drug control), Czech Republic. This certificate complies with the principles and guidelines of good manufacturing practice laid down in the directive 2003/94/EC which stipulates the requirements to fulfil GMP recommendations of WHO.
Baddi manufacturing unit of the company was inspected by the leading European regulator, SUKL, Czech Republic in the week of October 21, 2019.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1455.00 |
Dr. Reddys Lab | 5730.85 |
Cipla | 1459.75 |
Zydus Lifesciences | 1007.20 |
Lupin | 1564.60 |
View more.. |